Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis

The Janssen Pharmaceutical Companies of Johnson & Johnson JNJ announced new three-year data from the long-term extension (LTE) of the Stelara (ustekinumab) Phase 3 UNIFI study.
Investigators designed the trial to evaluate the safety and efficacy of induction and maintenance doses for the treatment in moderate to severely active ulcerative colitis patients.
The study enrolled adults who could not tolerate conventional treatments, such as corticosteroids and immunomodulators or biologics.
In three-year data from the Unifi phase 3 trial of the 348 patients, 55.2% of adults who responded to treatment sustained remission for 152 weeks.
In addition, 96.4% of the patients in remission in week 152 were corticosteroid-free.
On the safety front, the study didn't flag any new risks.
Price Action: JNJ shares are up 0.35% at $169.67 during the market session on the last check Friday.

Momentum66.34

Growth49.69

Quality15.63

Value24.41

Short

Medium

Long